Expertise in
17
conditions

Changsheng S. Ma

63 Nongye Road, 
Zhengzhou, CN 
Expertise in
17
conditions
63 Nongye Road, 
Zhengzhou, CN 

Overview

Changsheng Ma practices practicing medicine in Zhengzhou, China.

Ma is highly rated in 17 conditions, according to our data. Their clinical expertise encompasses Atrial Fibrillation, Cardiac Tamponade, Acute Coronary Syndrome, Cardiac Ablation, and Percutaneous Coronary Intervention (PCI).

They are actively involved in clinical research, co-authoring 389 peer reviewed articles and participating in 5 clinical trials.

Locations

63 Nongye Road, Zhengzhou, 450002, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Prospective Randomized Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation
Prospective Randomized Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation
Enrollment Status: Completed
Publish Date: July 19, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension
Enrollment Status: Completed
Publish Date: May 07, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in the Stable Treatment of Patients With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia .
A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in the Stable Treatment of Patients With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia .
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drug: SHR-1209
Study Phase: Phase 3
To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study
To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study
Enrollment Status: Completed
Publish Date: November 15, 2021
Intervention Type: Drug
Study Drug: SPH3127
Study Phase: Phase 2
View 4 Less Clinical Trials

389 Total Publications

Thromboembolism and Bleeding Risks in Atrial Fibrillation: Outcomes of Oral Anticoagulation After Catheter Ablation.
Thromboembolism and Bleeding Risks in Atrial Fibrillation: Outcomes of Oral Anticoagulation After Catheter Ablation.
Journal: Journal of the American Heart Association
Published: August 31, 2026

Frequently Asked Questions about Changsheng S. Ma

Is Changsheng S. Ma a top-rated expert for Atrial Fibrillation?

MediFind is an objective health platform that identifies experts based on real-world data. Changsheng S. Ma is classified as an Distinguished expert for Atrial Fibrillation, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Changsheng S. Ma participate in research or clinical trials?

Yes. Changsheng S. Ma has published 389 articles and abstracts on conditions like Atrial Fibrillation. You can view a list of Changsheng S. Ma's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ma's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile